Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 16/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.62 |
| ▸ | NQO2 | P16083 | 10/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14493800 | 0.84 | MTNR1A (0.45) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL23181344 | 0.83 | ACACB (0.48) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL13649760 | 0.82 | MTNR1A (0.61) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL14294856 | 0.81 | NQO2 (0.44) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL12711174 | 0.81 | NQO2 (0.44) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL13368590 | 0.81 | KDR (0.43) | — | |
| SCHEMBL5181902 | 0.81 | MTNR1A (0.69) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL14316576 | 0.80 | MTNR1A (0.41) | MTNR1AMTNR1BNQO2 | |
| Hydrochloric Acid SCHEMBL5424338 | 0.80 | MTNR1A (0.68) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL13593540 | 0.79 | MTNR1A (0.41) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012154807-A1 | USE OF JASMONATES FOR MODULATING MELATONIN PRODUCTION AND CALCIFICATION OF THE PINEAL GLAND | BROADY HEALTH SCIENCES, LLC (US) | 2012-11-15 | — | — | WO | claimed |
| US-20120288485-A1 | USE OF JASMONE FOR MODULATING MELATONIN PRODUCTION AND CALCIFICATION OF THE PINEAL GLAND | Broady Health Sciences, LLC. (US) | 2012-11-15 | — | — | US | claimed |
| WO-2005063240-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HYPERTENSION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | claimed |
| US-4882137-A | MELATONIN | GENE LINK AUSTRALIA LIMITED (AU) | 1989-11-21 | — | — | US | claimed |
| WO-2024155777-A2 | COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS | DARE BIOSCIENCE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2021062298-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | ARTEREZ, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10407388-B2 | Thiourea derivatives as activators of RORα and pharmaceutical composition containing same | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2019-09-10 | — | — | US | disclosed |
| US-10086071-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2018-10-02 | — | — | US | disclosed |
| US-20050153885-A1 | administering aldosterone antagonists such as spironolactone and eplerenone, to increasing the parasympathetic and sympathetic activity | PALO ALTO INVESTORS | 2005-07-14 | — | — | US | disclosed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | disclosed |
| EP-0851855-B9 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | MACEF (FR) | 2003-05-21 | — | — | EP | disclosed |
| EP-0851855-B1 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | MACEF (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-6140372-A | N-(2-(2-ACETYL-7-METHOXYNAPHTH-1-YL)ETHYL)ACETAMIDE; SEDATIVES; MELATONIN DISORDERS; DRUGS; COSMETICS; ANTIDEPRESSANTS; PSYCHIATRIC DISORDERS, E.G., STRESS, ANXIOLYTIC AGENTS, INSOMNIA, SCHIZOPHRENIA, PSYCHOSIS | CEMAF AND LABORATORIES BESINS ISOVESCO S.A. (FR) | 2000-10-31 | — | — | US | disclosed |
| US-6004991-A | COMPOUNDS FOR COSMETICS WITH ENANTIOMORPHS | CEMAF AND LABORATOIRES BESINS ISCOVESCO S.A. (FR) | 1999-12-21 | — | — | US | disclosed |
| EP-0851855-A1 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | CEMAF (FR) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997006140-A1 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | CEMAF (FR) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | REN, MTNR1A, MTNR1B | MTNR1A 2/4885MTNR1B 3/4885NQO2 1987/4885 |
| US-10407388-B2 | Thiourea derivatives as activators of RORα and pharmaceutical composition containing same | RORA, RORB, ROR1 | MTNR1A 319/4885MTNR1B 804/4885NQO2 4195/4885 |
| US-20120288485-A1 | USE OF JASMONE FOR MODULATING MELATONIN PRODUCTION AND CALCIFICATION OF THE PINEAL GLAND | MTNR1A, NLN, MTNR1B | MTNR1A 1/4885MTNR1B 3/4885NQO2 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.